| Prev Close | 67.69 |
| Day Low/High | 67.85 / 69.87 |
| 52 Wk Low/High | 60.14 / 82.15 |
| Avg Volume | 9.46M |
CVS Health Corp. (CVS)
69.53
NYSE : Retail Trade
| Exchange | NYSE |
| Shares Outstanding | 1.29B |
| Market Cap | 87.54B |
| EPS | 6.50 |
| P/E Ratio | 27.29 |
| Div & Yield | 2.00 (2.95%) |
Latest News
Chart of the Day: Polarized Price Targets on Apple Stock Ahead of Earnings
Expectations for Apple are all over the place.
Market Participants Hold Their Collective Breath Ahead of Apple Earnings
The iPhone maker is a show-me stock ahead of its fiscal first-quarter results
Let's See If Friday's Sunshine Was More Than a Break in the Clouds: Market Recon
It's likely that investors will be closely watching the U.S.-China trade talks to see if the skies brighten longer term.
3 Key Bear Market Rules, 5 Bargain Buys and a Monthly Dividend Portfolio
Dow Theory presents tips for surviving a bear market, some top year-end stock bargains and a simple strategy for monthly income.
Real Money Post Industrial Average Continues to Outperform Dow and S&P 500
Buoying RMPIA during the first half of December were shares of Broadcom, Facebook and PayPal.
Time to Minimize Your Tax Bill With Tax-Loss Selling
Underwater positions on stocks you feel lukewarm about are prime candidates for tax selling.
The Real Money Post-Industrial Average Has Jumped 11% So Far This Year
For the month of November RMPIA climbed 1.2% month over month.
Jim Cramer: What If Trump Tweets Xi Forced Him to Ignite the 25% Tariff Fuse?
Here are 4 stocks that can be bought into the stock cyclone that might occur if things don't go the bulls way in the Argentine.
Real Money Post-Industrial Average Beat Nasdaq Comp in November's First Half
Our index of 30 cutting-edge companies fell ... but not as much as the Nasdaq did.
Jim Cramer: Why the Market Did What It Did Today and What Can Happen Tomorrow
Now for those of you haven't voted, please go and do so and don't vote this stuff just invest in it!
Expect Markets to Take a Breather on Election Day: Market Recon
Things may pick up in the afternoon -- here is how to play it and what sectors to be wary of.
Jim Cramer: These Are the Stocks to Buy on Canada Deal and the 4th Quarter
Straying from these names could land you in quicksand as the 4th quarter begins.
How Investors Can Profit by Focusing on This One Key Business Statistic
This important number can be quite predictive about what's likely to occur with a stock's price.
Profit by Focusing on Net Profit Margins
The key business statistic can be quite predictive about what's likely to occur with a stock's price.
How Does Five Below Stack Up Against Competitors?
Five Below's earnings and sales growth is impressive, but earnings per share comparison to its direct competitors make it expensive.
Jim Cramer: Focus on the Forest of Spend
We forgot that this nation is a nation based on consumption, not on industry, on sales, not on making things.
Jim Cramer: The Great Ones Disrupt Their Own
Two companies, PepsiCo and Constellation Brands, are disrupting their own businesses and getting no credit whatsoever for doing so.
Family Offices Inject Capital Into Budding Cannabis Industry
Family offices, which manage billions of dollars and have much fewer restrictions on how they deploy capital, have been wading into the cannabis space with increasing frequency.
'Death by Amazon' Greatly Exaggerated
Contrarians who bought several "dead men walking" retailers have pocketed big gains by defying conventional wisdom.
Rite Aid Shareholders Cheer Merger Failure, Call on CEO to 'Put House In Order'
Rite Aid CEO John Standley faces shareholders's scrutiny after the merger flop.
Will Rite Aid End Up Like Blockbuster?
After a failed merger with Albertsons, Rite Aid faces a difficult time on its own in a changing landscape.
Rite Aid's Rotten Week: How Will It Now Compete Against Walgreens, CVS?
A week of bad news for Ride Aid may be good news for its competitors Walgreens and CVS.
Closing Bell: LIVE MARKETS BLOG
The Nasdaq was the lone major index to close the day on a high note.
Jim Cramer: These CEOs Deserve the Benefit of the Doubt
Sometimes you gotta have faith, but you also have to be a little more skeptical.
Tesla Is Not Worth $420, No Matter What Musk Says: Market Recon
The erratic CEO and awful fundamentals make it impossible to value TSLA -- despite attractive technicals.
Amazon Aims to Boost Sales of Its Private Label Products This Prime Day
Prime Day 2018 is expected to generate $3.4 billion in sales, according to Coresight Research.
